Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
J Endovasc Ther. 2024 Oct;31(5):862-872. doi: 10.1177/15266028231166282. Epub 2023 Apr 20.
The purpose of this study was to assess the impact of oversizing in thoracic endovascular aortic repair (TEVAR) on early and long-term survival and major adverse events in patients with uncomplicated type B aortic dissection (TBAD).
Between January 2010 and December 2018, 226 patients who were diagnosed with uncomplicated TBAD and received TEVAR were analyzed retrospectively. The patients were divided into ≤5% oversizing (n=153) and >5% oversizing (n=73) groups. Primary end points were all-cause and aortic-related mortalities. Secondary end points were procedure-related complications, including retrograde type A aortic dissection (RTAD), endoleak, distal stent-induced new entry (SINE), and late reintervention. All-cause and aortic-related mortalities were assessed using the Kaplan-Meier survival method, while procedure-related complications were evaluated using a competing risk model with all-cause death as a competing risk.
Mean oversizing was 2.1%±1.5% in the ≤5% oversizing group and 9.6%±4.1% in the >5% oversizing group. Differences in the 30-day mortality and adverse events between the 2 groups were statistically insignificant. The freedom from all-cause mortality was comparable between the ≤5% oversizing group and the >5% oversizing group (≤5%: 93.3% at 5 years, >5%: 92.3% at 5 years, p=0.957). No significant difference was observed between both groups in the freedom from aortic-related mortality (≤5%: 95.0% at 5 years, >5%: 96.7% at 5 years, p=0.928). However, the competing risk analyses revealed that the cumulative incidence of RTAD was statistically significantly greater in the >5% oversizing group than in the ≤5% oversizing group (≤5%: 1(0.7%) at 5 years, >5%: 6(6.9%) at 5 years, p=0.007). All RTADs occurred within a year of TEVAR. The differences in the cumulative incidences of type I endoleak, distal SINE, and late reintervention were not significant between the 2 groups.
The differences in the 5-year all-cause mortality and aortic-related mortality between patients with uncomplicated TBAD who received TEVAR with ≤5% oversizing and those who got TEVAR with >5% oversizing were insignificant. However, oversizing >5% was considerably associated with an increased risk of RTAD within a year of TEVAR, suggesting that oversizing ≤5% may be the appropriate size for TEVAR in patients with uncomplicated TBAD.
For patients with uncomplicated TBAD, choosing oversizing ≤5% in endovascular treatment is beneficial to reduce the risk of postoperative retrograde type A aortic dissection. This finding provides a basis for stent size selection in endovascular repair. In addition, one year after TEVAR is the main time period for postoperative retrograde type A aortic dissection, and attention should be paid to the management and follow-up of this period.
本研究旨在评估胸主动脉腔内修复术(TEVAR)中过大的支架直径对无并发症 B 型主动脉夹层(TBAD)患者早期和长期生存及主要不良事件的影响。
回顾性分析 2010 年 1 月至 2018 年 12 月期间接受 TEVAR 治疗的 226 例无并发症 TBAD 患者的临床资料。将患者分为支架直径≤5%过度扩张(n=153)和>5%过度扩张(n=73)两组。主要终点为全因死亡率和主动脉相关死亡率。次要终点为与手术相关的并发症,包括逆行性 A 型主动脉夹层(RTAD)、内漏、远端支架内新发破口(SINE)和晚期再次介入治疗。采用 Kaplan-Meier 生存法评估全因死亡率和主动脉相关死亡率,采用竞争风险模型评估与手术相关的并发症(以全因死亡为竞争风险)。
支架直径过度扩张≤5%组的平均扩张率为 2.1%±1.5%,支架直径过度扩张>5%组的平均扩张率为 9.6%±4.1%。两组患者 30 天死亡率和不良事件发生率差异无统计学意义。支架直径过度扩张≤5%组和支架直径过度扩张>5%组的全因死亡率无显著差异(支架直径过度扩张≤5%组:5 年时为 93.3%,支架直径过度扩张>5%组:5 年时为 92.3%,p=0.957)。两组患者主动脉相关死亡率也无显著差异(支架直径过度扩张≤5%组:5 年时为 95.0%,支架直径过度扩张>5%组:5 年时为 96.7%,p=0.928)。然而,竞争风险分析显示,支架直径过度扩张>5%组的 RTAD 累积发生率显著高于支架直径过度扩张≤5%组(支架直径过度扩张≤5%组:5 年时为 1(0.7%),支架直径过度扩张>5%组:5 年时为 6(6.9%),p=0.007)。所有 RTAD 均发生在 TEVAR 术后 1 年内。两组患者的Ⅰ型内漏、远端 SINE 和晚期再次介入治疗的累积发生率差异无统计学意义。
支架直径过度扩张≤5%的无并发症 TBAD 患者接受 TEVAR 治疗与支架直径过度扩张>5%的患者相比,5 年全因死亡率和主动脉相关死亡率差异无统计学意义。然而,支架直径过度扩张>5%与 TEVAR 术后 1 年内 RTAD 的风险显著增加相关,提示在无并发症 TBAD 患者中,支架直径过度扩张≤5%可能是 TEVAR 的合适选择。
对于无并发症 TBAD 患者,选择支架直径过度扩张≤5%的血管内治疗有利于降低术后逆行性 A 型主动脉夹层的风险。这一发现为血管内修复术的支架选择提供了依据。此外,TEVAR 术后 1 年是术后逆行性 A 型主动脉夹层的主要时间窗,应注意这一时期的管理和随访。